-
Press Release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
-
Press Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
-
Story
Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech -
Press Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
-
Story
Supercharging R&D: How AI helps us to bring medicines to patients faster -
Press Release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
-
Press Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Press Release
Novartis and US government reach agreement on lowering drug prices in the US
-
Press Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan